{{Rsnum
|rsid=3740066
|Gene=ABCC2
|Chromosome=10
|position=101604207
|Orientation=minus
|ReferenceAllele=C
|GMAF=0.3044
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 7.7 | 50.8 | 41.5
| HCB | 4.4 | 44.4 | 51.1
| JPT | 9.1 | 38.6 | 52.3
| YRI | 7.9 | 42.9 | 49.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 4.4 | 44.4 | 51.1
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
[[rs3740066]], a SNP in the [[ABCC2]] gene, is reported to be associated with a higher risk of developing [[intrahepatic cholestasis of pregnancy]] (ICP) based on a study of ~70 Argentinian patients. ICP is associated with increased fetal risks such as premature birth or intrauterine death.

The risk allele is [[rs3740066(A)]], and the odds ratio for homozygous [[rs3740066(A;A)]] mothers is 4.44 (CI: 1.83 - 10.78), and for heterozygous mothers 1.65 (CI: 0.76 - 3.64), compared to [[rs3740066(G;G)]] mothers. {{PMID|17997497}}

{{PharmGKB
|RSID=rs3740066
|Name_s=ABCC2: 3972C>T
|Gene_s=ABCC2
|Feature=Exon/Syn
|Evidence=PubMed ID:19940846
|Annotation=The AUCs of irinotecan, SN-38, SN-38 glucuronide, and APC are influenced by rs3740066, rs2306283, rs35605, rs10276036, and rs717620 .
|Drugs=irinotecan; SN-38
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111616
}}

{{PharmGKB
|RSID=rs3740066
|Name_s=ABCC2:3972C>T
|Gene_s=ABCC2
|Feature=Exon/Syn
|Evidence=PubMed ID:17502832
|Annotation=In strong LD with the causative (-)24C>T.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145028
}}

{{PMID Auto
|PMID=22630058
|Title=ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients
}}

{{PMID Auto
|PMID=18395921
|Title=Role of ABCC2 common variants in intrahepatic cholestasis of pregnancy.
|OA=1
}}

{{PMID Auto
|PMID=18926681
|Title=Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease.
}}

{{PMID Auto
|PMID=19568750
|Title=MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3740066
|overall_frequency_n=3552
|overall_frequency_d=10758
|overall_frequency=0.330173
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=32
|n_articles=2
|n_articles_annotated=2
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23506516
|Title=A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy
}}

{{PMID Auto
|PMID=23556446
|Title=Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease
}}

{{PMID Auto
|PMID=22868256
|Title=A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}